Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now displays Revision: v3.4.2, and a government funding/operating status notice and the earlier Revision: v3.4.1 were removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH operating status. Updated the page to version v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedMinor UI and metadata updates: glossary display option added and footer text updated to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check92 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.